一项用于预防状细胞贫血中priapism的受控试验:氨酸尿素加安慰剂vs氨酸尿素加塔达拉菲尔
Ibrahim Musa Idris1, Aminu Abba Yusuf1, Ismail Isah Ismail2
1Aminu Kano Teaching Hospital/Bayero University Kano, Kano, Nigeria.
Blood
|March 12, 2025
概括
在状细胞贫血 (SCA) 中出现的复发性缺血性priapism 难以预防. 这项研究发现,随机对照试验可用于预防SCA男性的priapism是可行的.
科学领域:
- 血液学 血液学 血液学
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 临床试验 临床试验
背景情况:
- 复发性缺血性 priapism 是状细胞贫血 (SCA) 的严重并发症.
- 之前的预防偏爱症试验缺乏明确的疗效.
- 与SCA相关的嗜食症显著影响身体和心理社会福祉.
研究的目的:
- 评估一项随机对照试验的可行性,以预防SCA男性的priapism.
- 为了比较氨酸urea加tadalafil与氨酸urea加安慰剂在预防priapism发作中的疗效.
主要方法:
- 进行了一项随机的,双盲的第二阶段可行性试验.
- 64名男性 (18-40岁) 患有复发性SCA相关的嗜食症被纳入.
- 参与者接受了氨酸urea加安慰剂或氨酸urea加tadalafil.
主要成果:
- 该试验实现了高招聘率 (100%),保留率 (98.4%) 和坚持率 (93.5%).
- 后期分析显示,两只手臂中都显著减少了priapism发病率 (58.3%的常规护理,66.3%的实验).
- 严重的不良事件和住院情况在各组之间是相似的.
结论:
- 随机对照试验可用于预防SCA男性的priapism是可行的.
- 基尿素治疗暂时影响了精子参数,停止后恢复.
- 进一步的研究是有必要的,以建立在SCA中最佳的青症预防策略.
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
124
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
124
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
126
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
141
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
141